Outcome of type III Gaucher disease on enzyme replacement therapy: Review of 55 cases

Journal of Inherited Metabolic Disease

Volumn 30, Issue 6, 2007, Pages 935-942

  Davies, E H ^a   Erikson, A ^b   Collin Histed, T ^c   Mengel, E ^d   Tylki Szymanska, A ^e   Vellodi, A ^a  

^a Metabolic Unit   (United Kingdom)

^b UMEÅ UNIVERSITY   (Sweden)

^c Gaucher Association of the United Kingdom   (United Kingdom)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Child Health Institute   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; IMIGLUCERASE;

ADOLESCENT; ADULT; AGE; CHILD; DRUG MEGADOSE; ENZYME REPLACEMENT; EYE MOVEMENT; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PROGNOSIS; REVIEW; RISK FACTOR; SEIZURE; SPLENECTOMY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ENZYMES; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INTELLIGENCE TESTS; MALE; NERVOUS SYSTEM DISEASES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 37449000781     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0577-z     Document Type: Review

References (10)

1. Altarescu G, Hill S, Wiggs E, et al (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 138: 539-547.
2. Bendig AW (1957) The comparative validity of raw scores vs. stanine scores. J Gen Psychol 56: 291-292.
3. Davies EH, Surtees R, DeVile C, Vellodi AA (2007) Severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis 30: 768-782.
4. Dunder U, Kaartinen V, Valtonen P, et al (2000) Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J 14: 361-367.
5. Erikson A (1986) Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 326: 1-42.
6. Erikson A, Karlberg J, Skogman AL, Dreborg S (1987) Gaucher disease (type III): Intellectual profile. Pediatr Neurol 3: 87-91.
7. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE (2006) Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr 95: 312-317.
8. Matzner U, Herbst E, Hedayati KK, et al (2005) Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 14: 1139-1152.
9. Roces DP, Lullmann-Rauch R, Peng J, et al (2004) Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: A preclinical animal study. Hum Mol Genet 13: 1979-1988.
10. Vellodi A, Bembi B, de Villemeur TB, et al (2001) Management of neuronopathic Gaucher disease: A European consensus. J Inherit Metab Dis 24: 319-327.